Global Biopharma Industry Confidence Reaches Four-Year High Despite Geopolitical Headwinds

A GlobalData survey of 157 pharmaceutical professionals found that 55% of respondents felt optimistic about industry growth over the next 12 months, up from 46% in 2023. Despite challenges including US tariffs, MFN drug pricing reform, and the IRA, the industry has “absorbed significant disruption.” M&A activity has surged, with Q1 2026 deal value rising 71% year over year. Neurology and immunology were highlighted as therapeutic areas with significant advancement.